Skip to main content

Table 1 Character of included studies (prevention)

From: The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease

Study [first author, publish year] Country Study design Patient populations Sample size
(MSC/control)
Average age
(MSC/control)
Male (%)
(MSC/control)
HLA matching MSC source MSC dose Number of MSC infusions MSC infusion timing Maximum follow-up (month)
J Xiang, 2017 [33] China RCT ALL 32/32 5.5/5.2 56.3%/53.1% 6/6 Umbilical cord 1.0 × 106 cells/kg Once 4 h after HSCT 12
Gao L, 2016 [9] China RCT AML, MDS, ALL, 62/62 18–40 (62.9%)/18–40 (69.4%) 46.8%/48.4% 3/6–5/6 Umbilical cord 3 × 107 cells No more than 4 doses Monthly after HSCT 70
Shipounova I N, 2014 [34] Russia RCT Leukemia 39/38 34 (17–63) NR 6/6 Bone marrow (0.9–1.65) × 106/kg Once 19–54 days after HSCT 55
Liu, K, 2011 [25] China RCT ALL, AML, CML, high-risk patients 27/28 30/31.5 74.1%/67.9% 3/6–5/6 Bone marrow (3–5) × 105 cells/kg Once Within 24 h after HSCT 33.5
Ning H, 2008 [24] China RCT AML, CML, MDS, ALL, NHL 10/15 38/37 90.0%/86.7% 6/6 Bone marrow 3.4 × 105 cells/kg Once 4 h before HSCT 36
Kuzmina L A, 2012 [35] Russia RCT AML,MDS, ALL, CML, CLL 19/18 34/29 42.1%/38.9% NR Bone marrow 1.1 × 106 cells/kg Once 19-54 days (mid 30) after HSCT 32
Wu K H, 2013 [36] China RCT ALL, AML 8/12 9.8/8.5 62.5%/50.0% 4/6–5/6 Umbilical cord 7.2 × 106 cells/kg Once 4 h before HSCT 27
  1. ALL acute lymphoid leukemia, AML acute myeloid leukemia, MDS myelodysplastic syndrome, CML chronic myeloid leukemia, NHL non-Hodgkin lymphoma, CLL chronic lymphoid leukemia, NR not reported